Key questions include:

• How do you structure CDMO partnerships to balance speed, flexibility, and risk without overcomplicating your manufacturing network?
• What are the biggest misalignments between biopharma and CDMOs during scale-up – and how can they be avoided early?
• At what point should companies start designing for commercial-scale manufacturing, and how does that shape CDMO and supply chain decisions?